Clinical Trials Browser

INDUSTRY × trametinib × 90 days × Clear all

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04892017 2026-04-08

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1 Terminated

91 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03975829 2026-04-02

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Active not recruiting

163 enrolled

CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT07468071 2026-04-02

KontRASt-R

Phase 1/2 Not yet recruiting

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03340506 2026-04-01

Dabrafenib and/or Trametinib Rollover Study

Phase 4 Recruiting

100 enrolled

CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT06804824 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

220 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2 Active not recruiting

134 enrolled

Dermatologic

Melanoma

NCT05907304 2026-02-27

SEACRAFT-1

Phase 1 Active not recruiting

86 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Phase 3 Active not recruiting

78 enrolled

Dermatologic

Melanoma

NCT04666272 2026-02-19

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Active not recruiting

78 enrolled

Dermatologic

Melanoma

NCT05874414 2026-01-22

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Phase 1/2 Recruiting

74 enrolled

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Clinical Trials

KontRASt-03

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Pediatric Long-Term Follow-up and Rollover Study

KontRASt-R

Dabrafenib and/or Trametinib Rollover Study

Pan Tumor Rollover Study

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

SEACRAFT-1

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma